Atezolizumab, a PD-L1 inhibitor, blocks the interaction between PD-L1 on tumor cells and PD-1 on T-cells, thereby restoring T-cell-mediated cytotoxicity [1,4]. This evidence concerns the gene CD274 and neoplasm.